Long-term Follow-up for Sickle Cell Disease with BEAM-101
A Long-term Follow-up Study in Patients Who Received BEAM-101
- Age
- 14 – 37
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Beam Therapeutics Inc. · Industry
This trial is looking for patients who previously received BEAM-101 and are finishing another study. Those who join will be monitored for 13 years after receiving the treatment.
You may be able to join if
- I have received BEAM-101 in the previous study.
- I am completing the end-of-study visit for that study.
- I can provide signed consent as required.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
Loading trial locations…